Purnovate illustration

Pipeline > Purnovate

Purnovate, a wholly owned subsidiary of Adial Pharmaceuticals, Inc, is a pharmaceutical company focused on inventing and developing selective, potent, stable, and soluble adenosine receptor analogs agonists and antagonists. These classes of compounds have been associated with the treatment of a broad range of disease classes including pain, oncology, addiction, pulmonary, inflammation, and others.

Historically, the majority of these compounds have been limited to a nonclinical setting due in part to inadequate solubility profiles. Purnovate technology targets this limitation by delivering substantially improved solubility. These next-generation compounds have already demonstrated preclinical efficacy and are well-positioned for clinical translation.


Purnovate, Inc. selected PNV-5030 as the lead compound for its pain management program. PNV-5030 has shown in testing to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects across several therapeutic indications.

In pre-clinical studies, PNV-5030 alone exhibited significant pain reduction compared to the control group and had a similar effect to that of 1mg/kg morphine. Importantly, PNV-5030 administered with 1 mg/kg morphine provided a significant improvement in pain compared to 1 mg/kg morphine alone. Further, when combined with 1 mg/kg morphine, PNV-5030 achieved an increased level of pain reduction as that obtained with 2mg/kg morphine alone (but not significantly). These results are supportive of clinical evaluation of PNV-5030 to replace or reduce the use of opioids for pain relief.

Purnovate Compounds for Other Indications

Purnovate compounds have demonstrated in vivo effect in animal models of cancer, asthma, and diabetes. The company intends to work with world-class academic and commercial partners to continue to develop these programs as well as for programs to develop drug candidates for wound/burn healing, inflammatory bowel disease (IBD), and infectious diseases where inflammation is a key mediator of damage (e.g., cytokine storms).


Purnovate In Research Agreements with Leading Universities

University of Virginia School of Medicine

Purnovate Inc. has entered into a research agreement with Dr. Mark Roeser from the University of Virginia School of Medicine to develop new formulations of the Company’s proprietary adenosine compounds for wound healing through transdermal administration (i.e., through the skin).

We believe there is enormous market potential for a compound that can promote wound healing, while providing the advantage of easy transdermal administration. There are countless applications for such a therapy and the pressure ulcer wound market alone is expected to reach $11.2 billion by 2026, according to Fortune Business Insights.

University of California San Diego

Purnovate Inc.  has entered into a research collaboration agreement with the University of California San Diego (UC San Diego), a leading education and research university, and Dr. Peter Ernst, DVM, PhD, Professor of Pathology and an expert in the fields of immunology, inflammation and infectious disease, to further evaluate the Company’s proprietary adenosine analogs as a potential treatment for inflammatory diseases, including inflammatory bowel disease (IBD) and infectious diseases where a large immune response (i.e., cytokine storm) plays a significant role. IBD is a group of disorders that cause chronic inflammation (pain and swelling) in the intestines, including conditions such as Crohn’s disease and ulcerative colitis.

Medical College of Wisconsin

Purnovate has entered into a research collaboration with the Medical College of Wisconsin, a leading medical school, and Dr. John Auchampach, PhD, Professor and Vice Chair of the Department of Pharmacology and Toxicology. The goal of the collaboration is to further evaluate the Company’s proprietary adenosine analogs as potential treatments for diabetes and non-alcoholic steatohepatitis (NASH). NASH is the most severe form of non-alcoholic fatty liver disease involving liver inflammation (hepatitis) that can lead to life-threatening cardiovascular co-morbidities.